Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhaled Medications01:23

Inhaled Medications

362
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
362
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

280
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
280
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

2.7K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
2.7K
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

555
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
555
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

346
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
346
Chronic Obstructive Pulmonary Disease01:22

Chronic Obstructive Pulmonary Disease

1.4K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hepatitis C care cascade using direct-acting antivirals in rural new York State from 2013 to 2023: a retrospective observational study.

BMC infectious diseases·2026
Same author

Cardiovascular Disease Among Loggers and Commercial Fishermen: A Preliminary Risk Assessment.

Journal of agromedicine·2026
Same author

Two-Year Follow-Up Study of Health-Related Quality of Life Among Transgender and Gender Expansive Youth Receiving Gender-Affirming Care.

Transgender health·2024
Same author

Health Care Engagement in Disease Prevention and Management: Factors Influencing Chronic Disease Program Referral Adherence Among Non-Hispanic Black and Hispanic Men With Chronic Conditions.

American journal of men's health·2024
Same author

The Effect of Mandatory Fitness Requirements on Cardiovascular Events: A State-by-State Analysis Using a National Database.

Workplace health & safety·2024
Same author

Exploring Multiple Dimensions of Access to and Preferences for Telehealth Use.

Telemedicine reports·2023

Related Experiment Video

Updated: Aug 25, 2025

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

40.8K

Prescribing Patterns for Long-Acting Inhaled Bronchodilators Among Rural Adults With Chronic Obstructive Pulmonary

Wendy M Brunner1, Nadir Siddiqui2, Melissa B Scribani1

  • 1Research Institute, Bassett Medical Center, Cooperstown, NY, USA.

Journal of Clinical Medicine Research
|October 19, 2022
PubMed
Summary
This summary is machine-generated.

Prescriptions for long-acting inhaled bronchodilators (LABDs) for chronic obstructive pulmonary disease (COPD) were common in rural areas and did not vary by insurance payer. This suggests payer status is not a barrier to LABD access in this population.

Keywords:
Long-acting antimuscarinicsLong-acting beta2-agonistsPayerPrescriptionsRural

More Related Videos

Evaluating Regional Pulmonary Deposition using Patient-Specific 3D Printed Lung Models
07:56

Evaluating Regional Pulmonary Deposition using Patient-Specific 3D Printed Lung Models

Published on: November 11, 2020

4.4K
Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease
07:10

Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease

Published on: August 24, 2019

9.8K

Related Experiment Videos

Last Updated: Aug 25, 2025

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

40.8K
Evaluating Regional Pulmonary Deposition using Patient-Specific 3D Printed Lung Models
07:56

Evaluating Regional Pulmonary Deposition using Patient-Specific 3D Printed Lung Models

Published on: November 11, 2020

4.4K
Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease
07:10

Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease

Published on: August 24, 2019

9.8K

Area of Science:

  • Pulmonary Medicine
  • Health Services Research

Background:

  • Chronic obstructive pulmonary disease (COPD) significantly impacts rural populations in the USA.
  • Long-acting inhaled bronchodilators (LABDs) are crucial for COPD management but show underutilization.
  • Investigating prescription patterns by payer is essential for understanding access to COPD treatments.

Purpose of the Study:

  • To examine if prescription rates for long-acting inhaled bronchodilators (LABDs) differ among patients with chronic obstructive pulmonary disease (COPD) based on their insurance payer.
  • To assess potential disparities in LABD utilization within a rural healthcare network.

Main Methods:

  • A retrospective analysis of patients with confirmed COPD from April 2017 to December 2019.
  • Comparison of patient characteristics, including payer status, between those who received LABDs and those who did not.
  • Analysis of prescription patterns in the general COPD population and in a subgroup with COPD-related hospitalizations.

Main Results:

  • High LABD prescription rates (93.0%) were observed in the general COPD patient sample, with no significant differences by payer.
  • Among patients hospitalized for COPD, 84.2% received LABDs, again showing no payer-based disparity.
  • Patients with COPD-related hospitalizations who received LABDs were younger, had lower BMI, were more likely to smoke, and had higher hospitalization rates.

Conclusions:

  • Prescription rates for long-acting inhaled bronchodilators (LABDs) in this rural COPD cohort were high and not influenced by payer status.
  • Payer status does not appear to be a barrier to LABD utilization in this specific rural healthcare setting.
  • Further research may explore other potential barriers to LABD access and adherence.